Multicenter, Phase II Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Iodine-131 tositumomab; Tositumomab
- Indications B cell lymphoma; Lymphoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 23 Dec 2010 Actual end date changed from May 2008 to Jan 2010 as reported by ClinicalTrials.gov.
- 26 Oct 2010 New trial record